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Comparison of Adrenocorticotropic Hormone Stimulation Test
Results Started 2 versus 4 Hours after Trilostane Administration in
Dogs with Naturally Occurring Hyperadrenocorticism
C.M. Bonadio, E.C. Feldman, T.A. Cohen, and P.H. Kass
Background: Trilostane medical treatment of naturally occurring hyperadrenocorticism (NOH) in dogs is common, as
is use of the adrenocorticotropic hormone (ACTH) stimulation test (ACTHst) in monitoring response to treatment. There
is uncertainty regarding when the ACTHst should be started relative to time of trilostane administration.
Objective: To compare ACTHst results in dogs being treated for NOH with trilostane when the test is begun 2 versus
4 hours after trilostane administration.
Animals: Twenty-one privately owned dogs with NOH, each treated with trilostane for at least 30 days.
Methods: Each dog had 2 ACTHst completed, 1 started 2 hours and the other 4 hours after trilostane administration.
The second test was started no sooner than 46 hours and no later than 74 hours after the first.
Results: For all 21 dogs, the mean post-ACTH serum cortisol concentration from tests started 2 hours after trilostane
administration (5.4  3.7 lg/dL) was significantly lower (P = .03) as compared with results from the tests started 4 hours
after administration (6.5  4.5 lg/dL).
Conclusions: Results of ACTHst started at different times yield significantly different results. Dogs with NOH, treated
with trilostane, and monitored with ACTHst results should have all of their subsequent ACTHst tests begun at or about
the same time after trilostane administration.
Key words: Hyperadrenocorticism; Trilostane.
Naturally occurring hyperadrenocorticism (NOH;hypercortisolism) is a well-recognized endocrine
disorder in dogs. Approximately 85% of dogs with
NOH have an adrenocorticotropic hormone (ACTH)-
secreting pituitary tumor (pituitary-dependent hyperad-
renocorticism; PDH). The autonomous and excessive
secretion of ACTH results in secondary adrenocortical
hyperplasia and chronic excess in cortisol secretion
with associated clinical and biochemical abnormalities.
Approximately 15% of dogs with NOH have an
autonomous cortisol-secreting adrenocortical adenoma
or adenocarcinoma (ATH) which also results in
chronic excesses in circulating cortisol.1
Dogs with either PDH or ATH are commonly trea-
ted with trilostane, a drug that interferes with synthesis
of glucocorticoids by enzyme blockade.2 Trilostane
treatment, at appropriate doses and frequency of
administration, may control many of the clinical and
biochemical abnormalities associated with canine
NOH.3–7 However, there is uncertainty in the literature
regarding what test might serve as an objective, spe-
cific, and sensitive means of assessing therapeutic
response to trilostane.6–8 Results from such a test (if it
fulfills these criteria) should complement the more sub-
jective information determined from the owner history
and physical examination.
For decades, veterinarians have used ACTH stimu-
lation test (ACTHst) results to aid in assessing thera-
peutic response of dogs with NOH being treated with
mitotane (o,p’-DDD). This test has also been adopted
for the assessment of therapeutic response to trilos-
tane. Since trilostane began to be used as a medical
treatment for dogs with NOH approximately 15 years
ago, no other test has been widely accepted as a more
objective, specific, and sensitive means of assessing
therapeutic response.6–8 If ACTHst results are utilized
to aid in assessing trilostane dose, frequency of admin-
istration, or both, there is a question of when the test
should be started relative to time of trilostane adminis-
tration. In a previous study of dogs with NOH, post-
ACTH serum cortisol concentrations, when the test
was started 8–9 hours posttrilostane administration
(mean: 8.1  3.4 lg/dL), significantly less inhibition of
cortisol synthesis was demonstrated as compared with
tests begun 3–4 hours after administration (mean:
2.6  1.3 lg/dL).9 One conclusion from that study
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was that results of the ACTHst started 3–4 hours after
trilostane administration, in most dogs with NOH,
were more indicative of trilostane’s inhibition of corti-
sol synthesis than results from tests started 8–9 hours
after administration.9
Currently, the literature contains several recom-
mended times to begin ACTHst in trilostane-treated
dogs. Among the suggested times to begin testing after
trilostane administration are as follows: 2–3 hours,8
3 hours,9,10 2–4 hours,11 2–5 hours,12 2–6 hours,13,14
as long as 24 hours,15 and 4 hours if the drug is given
once daily or 8–12 hours if the drug is given twice
daily.16 The package insert that accompanies FDA-
approved trilostane recommends beginning ACTHst
4–6 hours after the drug has been administered.a
This study was designed to further our understanding
of trilostane’s effect on ACTHst results relative to its
time of administration in dogs with NOH. Results of
tests begun 2 hours after trilostane administration were
compared with results of tests begun 4 hours after.
Methods
Animals
The study included dogs evaluated at the Veterinary Medical
Teaching Hospital, University of California at Davis and at the
Animal Specialty and Emergency Center, Los Angeles, from Feb-
ruary 2012 through December 2012. For inclusion in this study
informed consent must have been obtained from each owner.
Also, each dog must have had a history and physical examination
consistent with NOH.12 Each dog must have had polyuria as an
owner concern and each must have had at least 4 of the following
6 clinicopathologic findings: serum activities of alkaline phospha-
tase or alanine aminotransferase above the reference range, or
both above the reference range, serum cholesterol concentration
above the reference range, serum urea nitrogen concentration
(SUN) below or in the lower half of the reference range. The
urine specific gravity had to have been <1.020, or there could
have been microbial growth on culture of urine.12 No dog could
have had an SUN above the reference range or glucosuria. Before
initiation of trilostane treatment, each dog must have had an
abdominal ultrasonographic examination performed. For each
dog, results of at least 2 of the following 3 screening tests (eg,
ACTHst, low-dose dexamethasone suppression test [LDDst], or
urine cortisol to creatinine ratio [UCCR]) must have been consis-
tent with NOH.12 Dogs need not have had all 3 screening tests.
A diagnosis of PDH was made if a dog had at least 2 of the
following 3 diagnostic test results: an LDDst result indicative of
PDH (transient suppression of serum cortisol concentration),
ultrasonographic evidence of 2 relatively equal-sized adrenal
glands with no evidence of an adrenal gland tumor, or plasma
concentration of endogenous ACTH >45 pg/mL.6,17,18 A diagno-
sis of ATH was made if all of the following were present: a
LDDst result consistent with ATH, ultrasonographic evidence of
an adrenal mass, and, after trilostane control of NOH, histologic
confirmation of an adrenocortical tumor (adenoma or carci-
noma).6,17–19
Treatment and Assessment
Each dog must have been treated with FDA-approved, com-
mercially available trilostane (Vetoryl)a for at least 30 days
before enrollment.3,10,12,15 Resolution of NOH-related clinical
signs and biochemical changes were not inclusion requirements
to increase the likelihood that a spectrum of results, similar to
those encountered in any practice, would be included.
Each dog underwent 2 ACTHst, one initiated 2 hours and the
other 4 hours after trilostane administration. The second test was
started no sooner than 46 hours and no later than 74 hours after
the first. Dogs with PDH, separately from dogs suspected and
later confirmed to have had ATH, were to be numbered as they
were entered into the study, beginning with 1. Odd-numbered
dogs had the 2-hour test first and even-numbered dogs had the 4-
hour test first. Neither dose nor frequency of trilostane adminis-
tration was changed after the first test in any dog. For the ACT-
Hst, blood samples (2 mL each) were collected before and 1 hour
after each dog was given 0.25 mg of reconstituted lyophilized
ACTH (Cortrosyn) as an IM injection.b
Hormone Assay
Blood samples obtained for determination of plasma endoge-
nous ACTH concentration were collected, stored, and assayed as
previously described.1 Serum cortisol concentrations were mea-
sured by use of a commercial cortisol radioimmunoassayc that
has been validated for the use in dogs.10 The analytic sensitivity
of this radioimmunoassay was 0.3 l/dL. All serum samples were
batched and assayed together after all of the dogs had been
tested.
Statistical Analysis
Paired samples from the same dogs were analyzed using the
exact Wilcoxon signed-rank test. Comparisons between the 2
groups of patients were made using the exact Mann-Whitney test.
Testing was performed using commercial statistical software.d
Results are presented as mean  SD and median with range, as
indicated. Statistical significance was set at P < .05.
Results
Twenty-one client-owned dogs met the inclusion cri-
teria. Four dogs had ATH and 17 had PDH. The 21
dogs included 10 males and 11 females; 19 purebred
dogs and 2 mixed breed dogs. The following breeds
were represented: Labrador Retriever (2 dogs), English
Bulldog (2 dogs), Beagle (2 dogs), Australian Cattle
dog, Shih Tzu, Coton de Tullier, Chihuahua, Basset
Hound, German Shepherd Dog, Jack Russell Terrier,
Airedale Terrier, Maltese, Chesapeake Bay Retriever,
Rhodesian Ridgeback, Dachshund, and Springer Span-
iel (1 each). The mean age of the dogs was 10.7 years
(median 10 years) with a range of 7–14 years of age.
Mean body weight of the dogs was 20.7 kg (median
17 kg) with a range of 4.1–42.2 kg. Mean trilostane
dosage was 0.61 mg/kg PO q12h (median 0.5 mg/kg
PO q12h) with a range of 0.1–1.5 mg/kg PO q12h.
Group 1 had 9 dogs with PDH and 2 with ATH.
Group 2 had 8 dogs with PDH and 2 with ATH.
Group 1 dogs underwent the 2-hour posttrilostane-
administration ACTHst first and Group 2 dogs under-
went the 4-hour posttrilostane-administration ACTHst
first. There was no significant difference comparing the
first and second set of basal cortisol concentrations
obtained from the 11 Group 1 dogs (2.2  1.3 and
2.9  2.1 lg/dL, respectively). There was no significant
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difference comparing the first and second set of basal
cortisol concentrations obtained from the 10 Group 2
dogs (3.0  2.0 and 3.2  3.3 lg/dL, respectively).
There also was no significant difference in comparing
either set of basal serum cortisol concentrations from
the Group 1 dogs with either set of basal serum corti-
sol concentrations from the Group 2 dogs. Further-
more, there were no significant differences between
Group 1 and Group 2 dogs for either 2 or 4 hours
post-ACTH serum cortisol concentrations (P = .29).
Therefore, results from the ACTHst started 2 hours
after trilostane administration from both groups were
combined as were all results from ACTHst started
4 hours after trilostane administration.
For all 21 dogs, the post-ACTH serum cortisol con-
centrations from tests initiated 2 hours after trilostane
administration (5.4  3.7 lg/dL) were significantly
lower (P = .03) as compared with results from tests
started 4 hours after administration (6.5  4.5 lg/dL).
One dog had a post-ACTH serum cortisol concentra-
tion <1.5 lg/dL (1.4 lg/dL) on the 2-hour test. The
result after the 4-hour test, in that dog, was 2.5 lg/dL.
No other post-ACTH serum cortisol concentration
was <1.5 lg/dL. One of the 21 dogs had identical
post-ACTH serum cortisol concentrations (3.7 lg/dL)
on both tests. Fifteen of the 21 dogs (71%, 95% confi-
dence interval, 48–89%; including 3 dogs with ATH)
had a lower post-ACTH serum cortisol concentration
on ACTHst started 2 hours after trilostane had been
given as compared with the result when testing was
started 4 hours after (Fig 1). Five of the 21 dogs
(24%, 95% confidence interval, 8–47%; including 1
dog with ATH) had a lower post-ACTH serum corti-
sol concentration on ACTHst started 4 hours after
trilostane had been given as compared with the result
when testing started 2 hours after (Fig 2).
Discussion
The results of an ACTHst can be of value in moni-
toring and adjusting trilostane dosage in dogs treated
for NOH.8 It is hoped that trilostane-treated dogs
would respond favorably and survive for an extended
period of time once treatment has been initiated. The
manufacturer of trilostane recommends monitoring
dogs with an ACTHst 10–14 days after beginning
medication and again “at 30 days, 90 days, and every
3 months thereafter.”a It is also recommended that an
ACTHst be conducted 10–14 days after every trilos-
tane dose adjustment. Results of this study, however,
indicate that the 4–6 hour posttrilostane starting time
recommended for ACTHsta would likely yield higher,
and potentially misleading results as compared with
tests started 2 hours after trilostane administration.
Furthermore, although not evaluated, it is likely that
ACTHst begun 4 hours after trilostane administration
would yield lower results as compared with those
begun 6 hours after.
The reason for repeatedly obtaining ACTHst results
from trilostane-treated NOH dogs is that response to
treatment is not consistently predictable from assess-
ment of history and physical examination. As previously
discussed, the ACTHst is accepted as the most informa-
tive biochemical test for monitoring this treatment. Tril-
ostane dose and frequency of administration may need
to be periodically altered to achieve the desired
response, and results from the ACTHst are used to
provide an objective assessment of response to comple-
ment owner opinion and physical examination findings.
If ACTHst results are not reliable, not consistent, or
misleading, inappropriate adjustments in dose or fre-
quency of administration may be implemented. For
example, post-ACTHst serum cortisol concentration
Fig 1. Individual postadrenocorticotropic hormone stimulation
serum cortisol concentrations from 15 dogs with naturally occur-
ring hyperadrenocorticism whose results on tests started 2 hours
after the administration of trilostane were lower than on tests
begun 4 hours after. The 3 data sets with symbols are the results
from 3 dogs with adrenocortical tumor-associated hyperadreno-
corticism, all other data sets are from dogs with pituitary-depen-
dent hyperadrenocorticism.
Fig 2. Individual postadrenocorticotropic hormone stimulation
serum cortisol concentrations from 5 dogs with naturally occur-
ring hyperadrenocorticism whose results on tests started 4 hours
after the administration of trilostane were lower than results on
tests begun 2 hours after. The data set with symbols is the results
from the dog with adrenocortical tumor-associated hyperadreno-
corticism, all other data sets are from dogs with pituitary-depen-
dent hyperadrenocorticism.
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<1–1.5 lg/dL may be documented and trilostane dose
decreased before clinical over dosage occurs. Such a
result may be missed, however, if the test is begun after
trilostane effect has begun to dissipate postadministra-
tion. Similarly, post-ACTHst serum cortisol concentra-
tions >5.5–6.5 lg/dL may prompt an increase in the
trilostane dose in an attempt to improve response or
before signs of under dosage are seen and become intol-
erable. However, a post-ACTH serum cortisol concen-
tration >5.5–6.5 lg/dL may be documented in a dog
that may have had lower serum cortisol concentrations
had the test been started earlier in the day. If it is arbi-
trarily assumed that a difference in 2- versus 4-hour
post-ACTHst serum cortisol concentrations >20%
would not be clinically acceptable, 14 of the 21 dogs
(66%) had unacceptable differences in results. If it is
arbitrarily assumed that 1 post-ACTH serum cortisol
concentration <5.5 lg/dL and 1 >5.5 lg/dL would not
be clinically acceptable, 6 of the 21 dogs (28%) had
unacceptably different results. Additional studies are
needed to indicate whether it might be of benefit to have
new guidelines for interpreting ACTHst results relative
to time after trilostane administration.
Veterinarians are instructed, in the literature, to
begin ACTHst testing 2–24 hours after trilostane is
administered to dogs with NOH.8–16 As demonstrated
in an earlier study, ACTHst begun 3–4 hours after tril-
ostane administration yielded significantly lower results
when compared with tests begun 8–9 hours after.9
Results from this study demonstrate significantly lower
post-ACTH serum cortisol concentrations when results
of testing begun 2 hours after trilostane administration
were compared with results from tests begun 4 hours
after. Furthermore, although the number of dogs with
ATH was relatively small, there was no evidence of dif-
ference in response or need for different timing recom-
mendations for dogs with ATH versus those with PDH.
When monitoring dogs treated for NOH with trilos-
tane, veterinarians usually assume that each set of
ACTHst results can be compared directly with previ-
ous results to determine trends in response. Also, when
monitoring such dogs, it is assumed that dose require-
ments occasionally may need to be altered to meet
patient needs. To meet the criteria suggested in the
introduction, this objective assessment should be as
consistently reliable as possible if used to complement
owner opinion and physical examination findings.
Results of this study demonstrate that post-ACTHst
serum cortisol concentrations in a dog with NOH
being treated with trilostane are significantly influenced
by varying the starting time of the test as little as
2 hours after the drug was given. Therefore, the ACT-
Hst in each trilostane-treated dog should be started at
or about the same time postadministration to have the
strongest chance for repeatable results. The insert pro-
vided with FDA-approved trilostane states that “maxi-
mal plasma concentrations of trilostane occur within
1.5 hours” of administration in healthy dogs.a From
results of this study, it would appear likely that this
time from administration to maximal plasma concen-
trations is similar in dogs with NOH and that starting
ACTHst approximately 2 hours after administration
results in lower cortisol concentrations than at 4 hours
or later.9
Veterinarians treating dogs for NOH should avoid
the confusion of trying to determine if a change in
ACTHst results indicates need for dose adjustment or
is the change simply reflective of the time at which the
test was started. Regardless of the time postadminis-
tration chosen for testing, that approximate time
should be used for all subsequent testing. Lower serum
cortisol concentrations should be anticipated if testing
is begun approximately 2 hours posttrilostane adminis-
tration as compared with starting the test later.
Conclusion
Results of ACTHst started at 2 versus 4 hours after
administration of trilostane yielded significantly differ-
ent results. In a previous study, ACTHst results in dogs
with NOH treated with trilostane were significantly
lower if the test was started approximately 3 hours
after trilostane administration as compared with results
if the test was started approximately 9 hours after tril-
ostane administration. It is recommended that dogs
with NOH being treated with trilostane and monitored
with ACTHst results have each test begun at or about
the same time after administration of trilostane.
Footnotes
a Vetoryl [package insert]. Dechra Veterinary Products, Overland
Park, KS 2008
b Cortrosyn, Amphastar Pharmaceuticals Inc, Rancho Cuca-
monga, CA
c Coat-a-count cortisol assay, Diagnostic Products Corp, Los
Angeles, CA
d StatXact-9, Cytel Software Corporation, Cambridge, MA
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